image
Technology - Software - Application - NYSE - US
$ 9.79
-0.911 %
$ 924 M
Market Cap
244.75
P/E
1. INTRINSIC VALUE

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services.[ Read More ]

The intrinsic value of one ENFN stock under the base case scenario is HIDDEN Compared to the current market price of 9.79 USD, Enfusion, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ENFN

image
FINANCIALS
175 M REVENUE
16.09%
11.9 M OPERATING INCOME
199.87%
9.25 M NET INCOME
169.77%
25.6 M OPERATING CASH FLOW
81.08%
-9.67 M INVESTING CASH FLOW
-21.94%
-43.1 M FINANCING CASH FLOW
-441.31%
51.2 M REVENUE
3.46%
2.98 M OPERATING INCOME
10.28%
2.46 M NET INCOME
34.50%
16.2 M OPERATING CASH FLOW
120.97%
-2.78 M INVESTING CASH FLOW
51.37%
-14 K FINANCING CASH FLOW
12.50%
Balance Sheet Decomposition Enfusion, Inc.
image
Current Assets 69.9 M
Cash & Short-Term Investments 35.6 M
Receivables 28.1 M
Other Current Assets 6.18 M
Non-Current Assets 39.1 M
Long-Term Investments 0
PP&E 32.6 M
Other Non-Current Assets 6.5 M
Current Liabilities 20.3 M
Accounts Payable 2.21 M
Short-Term Debt 8.51 M
Other Current Liabilities 9.58 M
Non-Current Liabilities 11.2 M
Long-Term Debt 11.2 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Enfusion, Inc.
image
Revenue 175 M
Cost Of Revenue 57.6 M
Gross Profit 117 M
Operating Expenses 105 M
Operating Income 11.9 M
Other Expenses 2.7 M
Net Income 9.25 M
RATIOS
66.97% GROSS MARGIN
66.97%
6.85% OPERATING MARGIN
6.85%
3.45% NET MARGIN
3.45%
11.23% ROE
11.23%
5.53% ROA
5.53%
16.62% ROIC
16.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enfusion, Inc.
image
Net Income 9.25 M
Depreciation & Amortization 9.99 M
Capital Expenditures -9.67 M
Stock-Based Compensation 7.46 M
Change in Working Capital -9.44 M
Others 2.25 M
Free Cash Flow 16 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Enfusion, Inc.
image
ENFN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Enfusion, Inc.
image
Sold
0-3 MONTHS
32.2 K USD 2
3-6 MONTHS
622 K USD 4
6-9 MONTHS
1.18 K USD 2
9-12 MONTHS
12.5 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 weeks ago
Oct 22, 2024
Sell 6.03 K USD
Campobasso Matthew
General Counsel
- 674
8.95 USD
2 months ago
Sep 10, 2024
Sell 26.1 K USD
Bastone Bronwen
Chief People Officer
- 3219
8.12 USD
4 months ago
Jun 18, 2024
Sell 10.3 K USD
Gutowski Valeria
Chief Accounting Officer
- 1258
8.17 USD
4 months ago
Jun 18, 2024
Sell 13.5 K USD
Campobasso Matthew
General Counsel
- 1651
8.17 USD
4 months ago
Jun 18, 2024
Sell 86.1 K USD
Bastone Bronwen
Chief People Officer
- 10539
8.17 USD
4 months ago
Jun 20, 2024
Sell 148 K USD
Bastone Bronwen
Chief People Officer
- 18241
8.11 USD
5 months ago
Jun 14, 2024
Sell 38.9 K USD
Somers Deirdre
Director
- 4629
8.4 USD
5 months ago
May 20, 2024
Sell 325 K USD
Bastone Bronwen
Chief People Officer
- 34059
9.55 USD
8 months ago
Feb 29, 2024
Sell 943 USD
Campobasso Matthew
General Counsel
- 108
8.73 USD
8 months ago
Feb 29, 2024
Sell 236 USD
Gutowski Valeria
Chief Accounting Officer
- 27
8.73 USD
10 months ago
Jan 10, 2024
Sell 15.3 K USD
Somers Deirdre
Director
- 1770
8.65 USD
10 months ago
Jan 08, 2024
Sell 12 K USD
Movchan Oleg
Chief Executive Officer
- 1295
9.23 USD
10 months ago
Jan 09, 2024
Sell 12.1 K USD
Movchan Oleg
Chief Executive Officer
- 1355
8.95 USD
10 months ago
Jan 08, 2024
Sell 4.36 K USD
Campobasso Matthew
General Counsel
- 472
9.23 USD
10 months ago
Jan 09, 2024
Sell 4.41 K USD
Campobasso Matthew
General Counsel
- 493
8.95 USD
10 months ago
Jan 08, 2024
Sell 18.4 K USD
Herring Bradley
Chief Financial Officer
- 1998
9.23 USD
10 months ago
Jan 09, 2024
Sell 18.7 K USD
Herring Bradley
Chief Financial Officer
- 2090
8.95 USD
10 months ago
Jan 08, 2024
Sell 3.61 K USD
Bastone Bronwen
Chief People Officer
- 391
9.23 USD
10 months ago
Jan 09, 2024
Sell 3.67 K USD
Bastone Bronwen
Chief People Officer
- 410
8.95 USD
11 months ago
Dec 14, 2023
Sell 1 M USD
Movchan Oleg
Chief Executive Officer
- 100000
10.01 USD
11 months ago
Dec 01, 2023
Sell 1.51 M USD
Movchan Oleg
Chief Executive Officer
- 150000
10.09 USD
11 months ago
Nov 27, 2023
Sell 9.86 M USD
Malherbe Stephen
10 percent owner
- 1000000
9.86 USD
1 year ago
Nov 14, 2023
Sell 49.8 K USD
Groman Dan
Chief Technology Officer
- 5000
9.97 USD
1 year ago
Oct 17, 2023
Sell 45.4 K USD
Groman Dan
Chief Technology Officer
- 5000
9.09 USD
1 year ago
Sep 19, 2023
Sell 45.4 K USD
Groman Dan
Chief Technology Officer
- 5000
9.07 USD
1 year ago
Aug 14, 2023
Sell 323 USD
Bastone Bronwen
Chief People Officer
- 41
7.89 USD
1 year ago
Aug 14, 2023
Sell 13.9 K USD
Groman Dan
Chief Technology Officer
- 1760
7.89 USD
1 year ago
Aug 11, 2023
Sell 356 USD
Bastone Bronwen
Chief People Officer
- 44
8.1 USD
1 year ago
Aug 11, 2023
Sell 15 K USD
Groman Dan
Chief Technology Officer
- 1850
8.1 USD
1 year ago
Aug 10, 2023
Sell 17 K USD
Groman Dan
Chief Technology Officer
- 2106
8.08 USD
1 year ago
Aug 10, 2023
Sell 404 USD
Bastone Bronwen
Chief People Officer
- 50
8.08 USD
1 year ago
Aug 09, 2023
Sell 19.3 K USD
Groman Dan
Chief Technology Officer
- 2317
8.32 USD
1 year ago
Aug 09, 2023
Sell 458 USD
Bastone Bronwen
Chief People Officer
- 55
8.32 USD
1 year ago
Jul 17, 2023
Sell 43.8 K USD
Groman Dan
Chief Technology Officer
- 3877
11.31 USD
1 year ago
Jul 11, 2023
Sell 10.7 M USD
Hammoud Tarek
10 percent owner
- 1000000
10.7 USD
1 year ago
Jun 20, 2023
Sell 34.4 K USD
Groman Dan
Chief Technology Officer
- 3877
8.86 USD
1 year ago
May 22, 2023
Sell 31 K USD
Groman Dan
Chief Technology Officer
- 3877
8 USD
1 year ago
May 22, 2023
Sell 396 K USD
Groman Dan
Chief Technology Officer
- 50000
7.91 USD
1 year ago
May 10, 2023
Sell 126 K USD
Groman Dan
Chief Technology Officer
- 15048
8.34 USD
1 year ago
Apr 17, 2023
Sell 37.5 K USD
Groman Dan
Chief Technology Officer
- 3877
9.66 USD
1 year ago
Mar 17, 2023
Sell 42.4 K USD
Groman Dan
Chief Technology Officer
- 3877
10.94 USD
1 year ago
Mar 08, 2023
Sell 10.9 M USD
Hammoud Tarek
10 percent owner
- 1000000
10.92 USD
1 year ago
Mar 08, 2023
Sell 9.46 M USD
Hammoud Tarek
10 percent owner
- 870000
10.871 USD
1 year ago
Mar 08, 2023
Sell 11.4 M USD
Malherbe Stephen
10 percent owner
- 1000000
11.35 USD
1 year ago
Feb 17, 2023
Sell 42.4 K USD
Groman Dan
Chief Technology Officer
- 3877
10.93 USD
1 year ago
Jan 17, 2023
Sell 42.4 K USD
Groman Dan
Chief Technology Officer
- 3877
10.93 USD
2 years ago
Nov 14, 2022
Sell 95.8 K USD
Groman Dan
Chief Technology Officer
- 7000
13.69 USD
2 years ago
Nov 15, 2022
Sell 71.7 K USD
Groman Dan
Chief Technology Officer
- 5103
14.06 USD
2 years ago
Nov 14, 2022
Sell 356 K USD
Bachert Steven M.
Chief Revenue Officer
- 26000
13.69 USD
2 years ago
Nov 11, 2022
Sell 12.2 M USD
Hammoud Tarek
Director
- 1000000
12.15 USD
3 years ago
Oct 25, 2021
Sell 64.8 M USD
Bernstein Bradford E
director, 10 percent owner:
- 4075531
15.895 USD
3 years ago
Oct 25, 2021
Bought 12.3 M USD
Luo Roy
Director
+ 722707
17 USD
3 years ago
Oct 25, 2021
Bought 9.16 M USD
Luo Roy
Director
+ 538887
17 USD
3 years ago
Oct 25, 2021
Bought 12.3 M USD
ICONIQ Strategic Partners V, L.P.
10 percent owner
+ 722707
17 USD
3 years ago
Oct 25, 2021
Bought 9.16 M USD
ICONIQ Strategic Partners V, L.P.
10 percent owner
+ 538887
17 USD
3 years ago
Oct 25, 2021
Sell 10.3 M USD
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
10 percent owner
- 647862
15.895 USD
19 years ago
Nov 01, 2005
Bought 0 USD
WARSHAW KIRK M
Chief Financial Officer
+ 1950000
0 USD
7. News
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript Enfusion, Inc. (NYSE:ENFN ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - Chief Executive Officer Bradley Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Parker Lane - Stifel Kevin McVeigh - UBS Elise Kenner - JP Morgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Crispin Love - Piper Sandler Operator Good morning, ladies and gentlemen. Thank you for standing by. seekingalpha.com - 1 week ago
Here's What Key Metrics Tell Us About Enfusion (ENFN) Q3 Earnings The headline numbers for Enfusion (ENFN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
Enfusion, Inc. (ENFN) Q3 Earnings and Revenues Miss Estimates Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago. zacks.com - 1 week ago
Enfusion Announces Third Quarter 2024 Results NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 Earnings Conference Call Management will host a conference call today, November 4, 2024, at 8:30 AM ET. businesswire.com - 1 week ago
Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation NEW YORK--(BUSINESS WIRE)--Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company's position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innova. businesswire.com - 1 month ago
Enfusion Announces Date of Third Quarter 2024 Results NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM (ET) / 5:30 AM (PT) to discuss the results. To access this call, dial (888) 596-4144. The conference I. businesswire.com - 1 month ago
The Schall Law Firm Invites Investor Participation In An Inquiry Into Enfusion Inc For Violating Securities Laws LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 month ago
Enfusion, Inc. Is Being Looked Into For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 month ago
The Schall Law Firm Invites Investors To Help Investigate Whether Enfusion Inc Violated Securities Laws LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 month ago
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Enfusion, Inc. For Possible Securities Fraud LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 1 month ago
Enfusion Inc Is Being Investigated For Violating Securities Laws And The Schall Law Firm Seeks Investor Participation LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 month ago
8. Profile Summary

Enfusion, Inc. ENFN

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 924 M
Dividend Yield 0.00%
Description Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Contact 125 South Clark Street, Chicago, IL, 60603 https://www.enfusion.com
IPO Date Oct. 21, 2021
Employees 1102
Officers Mr. Joseph Defeo Global Head of Managed Services Production Mr. Oleg Movchan Chief Executive Officer & Director Mr. Neal Pawar Chief Operating Officer Ms. Valeria Gutowski Chief Accounting Officer Mr. Daniel Groman Chief Technology Officer Mr. Ignatius Tochukwu Njoku Head of Investor Relations Mr. Matthew R. Campobasso General Counsel & Corporate Secretary Ms. Bronwen Bastone Chief People Officer Mr. Bradley Herring Chief Financial Officer Mr. Stephen Malherbe Managing Partner